Blockade of Both CD28/B7 and OX40/OX40L Co-Stimulatory Signal Pathways Prolongs the Survival of Islet Xenografts
0301 basic medicine
Mice, Inbred BALB C
Membrane Glycoproteins
Graft Survival
Transplantation, Heterologous
Islets of Langerhans Transplantation
Antigens, Differentiation
Rats
3. Good health
Mice
03 medical and health sciences
0302 clinical medicine
CD28 Antigens
Rats, Inbred Lew
Tumor Necrosis Factors
B7-1 Antigen
Animals
DOI:
10.1016/j.transproceed.2005.10.117
Publication Date:
2005-12-29T07:13:10Z
AUTHORS (7)
ABSTRACT
CTLA4Ig, a recombinant fusion protein composed of the extracellular domain of human CTLA4 and the constant region of human IgG1, inhibits the interaction of CD28/B7 pathway by binding the B7 molecule. OX40Ig, a recombinant fusion protein composed of the extracellular domain of human OX40 and the constant region of human IgG1, abrogates the interaction of OX40/OX40L pathway by binding the OX40L on APCs. So blockade of CD28/B7 or OX40/OX40L co-stimulatory pathways alone in mice with CTLA4Ig or OX40Ig can result in finitely prolonging the survival of islet grafts (43.2 +/- 4.81 and 67.7 +/- 7.74 days, respectively). In this study, a novel replication-defective adenovirus containing both of the CTLA4Ig and OX40Ig genes, AdCTLA4Ig-IRES-OX40Ig, was constructed by homologous recombination and injected into the streptozocin-rendered diabetic BalB/c mouse recipients (H-2d) through the tail vein, at the same day, the freshly isolated islets from Lewis rats (RT-1) were transplanted under the left kidney capsule of the recipients. The results showed that the mean survival time of the islet xenografts in the AdCTLA4Ig-IRES-OX40Ig-treated diabetic mice was significantly prolonged (100.3 +/- 14.94 days), while those in the untreated or AdEGFP-treated mice were rejected in normal fashion (6.7 +/- 0.94 and 7.0 +/- 1.0 days, respectively). In conclusion, utilizing AdCTLA4Ig-IRES-OX40Ig in vivo which can simultaneously express CTLA4Ig and OX40Ig proteins can improve the survival of Lewis-->BalB/c islet xenografts.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (11)
CITATIONS (9)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....